Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 9.78 · gapped above the open, then crossed back over prior close. High/low 10.33 at 9:00 am ET, 9.67 at 11:30 am ET.
Olema Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the terms of the agreement, Novartis is providing Olema with ribociclib drug supply for the OPERA-02 trial, which we initiated in 2025.”
FILING10-K0001193125-26-107169cik 0001750284
“Under the terms of the 2025 Pfizer Agreement, we are responsible for conducting the clinical trial for the combined therapies and Pfizer is responsible for supplying atirmociclib to us at no cost.”
FILING10-K0001193125-26-107169cik 0001750284
“On October 17, 2024, we signed an out-license of our de-prioritized TRPM4 targeted research program to Black Shadow Therapeutics LLC in exchange for potential single-digit royalties on world-wide net sales should a product be approved by regulatory authorities.”
FILING10-K0001193125-26-107169cik 0001750284
“Under the terms of the Aurigene Agreement, Aurigene provides to us an exclusive license to its portfolio of novel small molecule inhibitors of the target.”
FILING10-K0001193125-26-107169cik 0001750284
“We successfully identified KAT6 as a novel target and entered into a collaboration with Aurigene Oncology in 2022, which led to the discovery and development of OP-3136.”
FILING10-K0001193125-26-107169cik 0001750284
“On January 5, 2024, we entered into a sales agreement (the 2024 Sales Agreement), with Cowen and Company, LLC (Cowen and Company), as sales agent, pursuant to which we were permitted to offer and sell, from time to time, shares of our common stock, having an aggregate offering price of up to $150.0 million (the 2024 ATM Shares).”
FILING10-K0001193125-26-107169cik 0001750284
“On January 6, 2025, we entered into a sales agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC, (TD Cowen) as sales agent, pursuant to which the Company could offer and sell, from time to time, shares of the Company's common stock, having an aggregate offering price of up to $150.0 million (the 2025 ATM Shares).”
FILING10-K0001193125-26-107169cik 0001750284
Watchlist prices, news filtered to it, and its next report on your desk.
Olema Pharmaceuticals, Inc. has 6 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Olema Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
OLMA (Olema Pharmaceuticals, Inc.) has 6 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.67%, in healthcare.